Rock Immune, Inc.
Denver, CO
- UEI
- M35ZNF9XP8Q7
- CAGE
- Not on record
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 3528 Xanthia St, Denver, CO 80238, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| CCR4-IL2 bispecific immunotoxin for targeted therapy of cutaneous t-cell lymphoma | National Cancer Institute (NIH) | $8,200,000 |
Quick answers
Is Rock Immune, Inc. registered in SAM.gov?
Yes. Rock Immune, Inc.'s SAM.gov registration is active through October 2, 2027.
What is Rock Immune, Inc.'s most recent federal award?
Rock Immune, Inc.'s most recent federal grant award is CCR4-IL2 bispecific immunotoxin for targeted therapy of cutaneous t-cell lymphoma (R42CA261547), from National Cancer Institute (NIH), on August 1, 2021.
On GovTribe
See Rock Immune, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors